GlassScriptPhysician profile
Charles M Geller
NPI 1417932880
$1,163.84
in general payments reported to CMS, 2019-2025
13 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2022: $32.59 · 2023: $71.39 · 2024: $21.44 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $752.95 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.46 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $68.07 | 2025 | Watchman Flx, Bodyguardian |
| Becton, Dickinson and Company | $32.59 | 2022 | |
| Smith+Nephew, INC. | $27.36 | 2019 | |
| Angiodynamics, INC. | $25.77 | 2025 | Alphavac |
| Janssen Pharmaceuticals, INC | $23.50 | 2019 | |
| Chiesi USA, INC. | $22.05 | 2025 | Kengreal |
| Getinge USA Sales, LLC | $21.44 | 2024 | Cardiohelp |
| Actelion Pharmaceuticals US, INC. | $20.14 | 2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $19.65 | 2025 | Onpattro |
| Novo Nordisk INC | $16.88 | 2023 | Rybelsus, Ozempic |
| Abiomed | $15.98 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.